OBJECTIVES: The high incidence of recurrence in superficial urothelial cancer warrants the use of chemoprophylaxis; however, the results achieved to date have been unsatisfactory. The present study investigated the possibility of reducing the incidence of recurrence of superficial urothelial cancer post-TUR and disease progression. METHODS/RESULTS: 99 patients were treated with monthly instillations of mitomycia-C and BCG alternately for one year, which commenced three weeks following TUR. The incidence of recurrence and progression were 15.3% and 5.10%, respectively. Treatment was well-tolerated and there were minimum side effects. CONCLUSIONS: Chemoprophylaxis with alternating mitomycin-C and BCG therapy in patients with superficial urothelial cancer achieves good results. It is well-tolerated and few side effects were observed.
|Journal||Archivos Espanoles de Urologia|
|Publication status||Published - 1 Sep 1996|
- Bladder cancer
- Prospective study